Agile Therapeutics, Inc. (AGRX) financial statements (2020 and earlier)

Company profile

Business Address 101 POOR FARM ROAD
PRINCETON, NJ 08540-1715
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18836493440
Cash and cash equivalents18836493440
Prepaid expense111341
Total current assets:20837523841
Noncurrent Assets
Property, plant and equipment141414121212
Prepaid expense     2
Deferred costs    00
Other noncurrent assets 00000
Other undisclosed noncurrent assets0     
Total noncurrent assets:141414121314
TOTAL ASSETS:342251645155
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities224554
Accounts payable113223
Accrued liabilities111331
Employee-related liabilities     1
Debt  11525
Derivative instruments and hedges, liabilities  0000
Other undisclosed current liabilities0    (1)
Total current liabilities:22141189
Noncurrent Liabilities
Long-term debt and lease obligation   111310
Long-term debt, excluding current maturities   111310
Total noncurrent liabilities:   111310
Total liabilities:2214222119
Stockholders' equity
Stockholders' equity attributable to parent322036423036
Common stock000000
Additional paid in capital286262258236194170
Accumulated deficit(254)(242)(222)(193)(165)(134)
Total stockholders' equity:322036423036
Other undisclosed liabilities and equity0     
TOTAL LIABILITIES AND EQUITY:342251645155

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(16)(20)(27)(30)(33)(19)
Operating loss:(16)(20)(27)(30)(33)(19)
Nonoperating income (expense)0(1)(1)000
Investment income, nonoperating000000
Interest and debt expense(0)(1)(2)(2)(3)(2)
Other undisclosed income from continuing operations before equity method investments, income taxes     0
Loss from continuing operations before equity method investments, income taxes:(17)(21)(30)(32)(36)(20)
Other undisclosed income (loss) from continuing operations before income taxes0120(0) 
Loss from continuing operations before income taxes:(16)(20)(28)(32)(36)(20)
Income tax benefit 0 364
Net loss available to common stockholders, diluted:(16)(20)(28)(29)(30)(16)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(16)(20)(28)(29)(30)(16)
Comprehensive loss, net of tax, attributable to parent:(16)(20)(28)(29)(30)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: